Halozyme Therapeutics: David A. Ramsay Files Initial Insider Ownership (Form 3)
| Field | Detail |
|---|---|
| Company | Ramsay David A |
| Form Type | 3 |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, form-3, new-executive, halozyme
TL;DR
**New insider David A. Ramsay just filed a Form 3 for Halozyme Therapeutics, signaling a fresh face in leadership.**
AI Summary
David A. Ramsay, a new insider at Halozyme Therapeutics, Inc., filed a Form 3 on March 23, 2026, indicating his initial beneficial ownership of securities. This filing is crucial for investors because it marks Ramsay's official entry as an insider, suggesting he has taken on a significant role within the company. While the filing itself doesn't detail the number of shares, it signals a new executive or director is now aligned with the company's future, which can be a positive indicator for shareholders.
Why It Matters
This filing signals a new insider, David A. Ramsay, has joined Halozyme Therapeutics, Inc., which could indicate new leadership or strategic direction for the company.
Risk Assessment
Risk Level: low — A Form 3 filing simply indicates a new insider's initial ownership and does not inherently carry significant risk.
Analyst Insight
Investors should monitor future filings (Form 4s) by David A. Ramsay to understand the extent and nature of his stock transactions, which could provide insights into his confidence in Halozyme Therapeutics, Inc.
Key Players & Entities
- RAMSAY DAVID A (person) — Reporting Person
- HALOZYME THERAPEUTICS, INC. (company) — Issuer
- 0001283292 (person) — CIK of Reporting Person
- 0001159036 (company) — CIK of Issuer
FAQ
What is the purpose of this Form 3 filing by David A. Ramsay?
This Form 3 filing, dated March 23, 2026, serves as an 'Initial statement of beneficial ownership of securities' for David A. Ramsay, indicating he has become an insider (e.g., officer, director, or 10% shareholder) of Halozyme Therapeutics, Inc.
Which company is David A. Ramsay now an insider of?
David A. Ramsay is now an insider of HALOZYME THERAPEUTICS, INC., as indicated by the Issuer's CIK 0001159036 in the filing.
Filing Stats: 420 words · 2 min read · ~1 pages · Grade level 9.3 · Accepted 2026-03-23 18:35:07
Filing Documents
- wk-form3_1774305304.html (3)
- wk-form3_1774305304.xml (3) — 2KB
- ramsay-edgarnextpoafinal.htm (EX-24) — 7KB
- ramsay-edgarnextpoafinal001.jpg (GRAPHIC) — 235KB
- ramsay-edgarnextpoafinal002.jpg (GRAPHIC) — 214KB
- 0001159036-26-000045.txt ( ) — 628KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * RAMSAY DAVID A (Last) (First) (Middle) C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL (Street) SAN DIEGO CALIFORNIA 92130 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/23/2026 3. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS, INC. [ HALO ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Interim CFO 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: Remarks: Exhibit List: Exhibit 24 - Power of Attorney No securities are beneficially owned. /s/ James R. Oehler, Attorney-in-Fact 03/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)